NRX Pharmaceuticals, Inc.
NRXP
Jodie situation report
NRX Pharmaceuticals, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 11 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.
- NRXP's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if NRXP's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind NRXP
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
COHNFiling-linked nameinvesteeMay 15, 2026 ▾
“5 Table of Contents HOPE Therapeutics ● Completed acquisition of Dura Medical and subsequent acquisition of an interest in Cohen and Associates, LLC with first clinical revenue recorded during third quarter of 2025.”
PFEPfizer, Inc.competitorMar 23, 2026 ▾
“Our chief competitors in the psychiatry area include companies such as Johnson & Johnson, Pfizer, Eli Lilly, Sage Therapeutics, Axsome, and Relmada, among others.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
NRXP is currently a Follower in the organic co-movement group Autonomous Technology & Services. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for NRXP; it is not active in the latest market snapshot.